ClinicalTrials.gg
CompletedNCT02420379Updated Jan 25, 2021Results posted

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

A Phase 2 interventional study of eteplirsen in Duchenne Muscular Dystrophy (DMD), sponsored by Sarepta Therapeutics, Inc.. Completed at 13 sites in United States. Open to male participants aged 4 Years to 6 Years. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Sarepta Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
4 Years to 6 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
3rd of 11
33 · median 15
Started
2015
the only one that year
Phase 2
7 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 7 in phase 2, and was the 7th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 6 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

This is an open-label study to assess the safety, tolerability, efficacy and pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Read the detailed description

Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.

Clinical efficacy, including functional tests and MRI, will be assessed at regularly scheduled study visits. Patients will undergo one baseline and one follow-up muscle biopsy.

Population and serial PK will be collected.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • DMD
  • Duchenne muscular dystrophy
  • eteplirsen
  • Dystrophin
  • exon 51
04

Who can participate

Ages eligible
4 Years to 6 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male 4-6 years of age.
  • Diagnosis of DMD, genotypically confirmed.
  • Stable dose of oral for at least 12 weeks or has not received corticosteroids for at least 12 weeks.
  • Intact right and left biceps muscles or two alternative upper arm muscle groups.
  • Parent that is willing to provide consent and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Use of any pharmacologic treatment (other than ) within 12 weeks that may have an effect on muscle strength or function (e.g., growth hormone, anabolic steroids).
  • Previous or current treatment with any other experimental treatments within 12 weeks or participation in any other clinical trial within 6 months.
  • Major surgery within 3 months prior to the first dose of study drug, or planned surgery during this study which would interfere with the ability to perform study activities.
  • Presence of other illness.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Open-Label

    Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .

    Drug: eteplirsen

  • No intervention
    Control Group

    Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.

Interventions

  • Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.

    Also known as: AVI-4658, EXONDYS 51®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation

    Adverse Event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug \[up to 100 weeks\]) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

    Time frame: Baseline up to 100 weeks

  2. Number of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEs

    Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

    Time frame: Baseline up to 100 weeks

  3. Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs

    Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

    Time frame: Baseline up to 100 weeks

  4. Number of Participants With at Least One Abnormal Physical Examination Finding

    Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Number of participants with at least one abnormal physical examination findings were reported. Abnormality in physical examinations was based on Investigator's discretion.

    Time frame: Baseline up to 100 weeks

  5. Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEs

    Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECGs were reported as TEAEs.

    Time frame: Baseline up to 96 weeks

  6. Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEs

    Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECHO were reported as TEAEs.

    Time frame: Baseline up to 96 weeks

Secondary outcomes

  1. Change From Baseline in Dystrophin Protein Levels Quantified by Western Blot at Week 48 and 96

    Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Week 48 and 96 was reported. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.

    Time frame: Baseline, Week 48 and 96

  2. Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 and 96

    Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry at Week 48 and 96 was reported.

    Time frame: Baseline, Week 48 and 96

07

Results

Posted Jul 22, 2020

Participant flow

The study was conducted at 13 sites in the United States.

Participant flow — Overall Study
MilestoneEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
Started267
Completed253
Not completed14
Withdrew: Withdrawal by subject03
Withdrew: Unable to complete due to schooling01
Withdrew: Transitioned to commercial drug10

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation

Adverse Event (AE) was any untoward medical occurrence in a participant that did not necessarily have a causal relationship with the study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment emergent adverse events were events that developed or worsened during the on-treatment period (defined as time from first dose of study drug and up to 28 days after last dose of study drug \[up to 100 weeks\]) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
ParticipantsEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
Participants with TEAEs265
Participants with Serious TEAEs40
Participants with TEAEs leading to discontinuation00
PrimaryNumber of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEs

Laboratory parameters included hematology, serum chemistry (SC), urinalysis and coagulation. Number of participants with at least one potentially clinically significant abnormal findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEs
ParticipantsEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
SC: Blood creatine phosphokinase increased10
Hematology: Anaemia10
Hematology: Iron deficiency Anaemia10
Urinalysis: chromaturia30
Urinalysis: pollakiuria10
Coagulation: Thrombocytopenia00
PrimaryNumber of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs

Vital sign parameters included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and body temperature. Number of participants with at least one potentially clinically significant abnormal vital signs findings were reported as TEAEs. The Investigator determined whether abnormal assessment results were clinically significant or not clinically significant. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care.

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEs
ParticipantsEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
Pyrexia111
Pulse pressure increased10
Tachycardia10
PrimaryNumber of Participants With at Least One Abnormal Physical Examination Finding

Physical examinations, full and brief, were performed by the Investigator, a physician Sub-Investigator, or a Nurse Practitioner (if licensed in the state or province to perform physical examinations). Full physical examinations included examination of general appearance; head, ears, eyes, nose, and throat; heart; lungs; chest; abdomen; skin; lymph nodes; and musculoskeletal and neurological systems. Number of participants with at least one abnormal physical examination findings were reported. Abnormality in physical examinations was based on Investigator's discretion.

Time frame:
Baseline up to 100 weeks
Reported as:
Count of participants · Participants
Number of Participants With at Least One Abnormal Physical Examination Finding
ParticipantsEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
Number of Participants With at Least One Abnormal Physical Examination Finding234
PrimaryNumber of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEs

Twelve-lead ECGs and Holter ECGs were performed at a consistent time of day throughout the study. Electrocardiograms were performed only after the participant was in the supine position, resting, and quiet for a minimum of 15 minutes. The ECG was manually reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECGs were reported as TEAEs.

Time frame:
Baseline up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEs
ParticipantsEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
Number of Participants With Abnormalities in Electrocardiograms (ECGs) Reported as TEAEs10
PrimaryNumber of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEs

Standard, 2-dimensional ECHOs were performed at a consistent time of day throughout the study. Cardiac function events included cardiomegaly, tachycardia, and dyspnoea. The ECHO was reviewed and interpreted by medically qualified personnel. Number of participants with at least one abnormalities in ECHO were reported as TEAEs.

Time frame:
Baseline up to 96 weeks
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEs
ParticipantsEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
Number of Participants With Abnormalities in Echocardiograms (ECHO) Reported as TEAEs10
SecondaryChange From Baseline in Dystrophin Protein Levels Quantified by Western Blot at Week 48 and 96

Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot at Week 48 and 96 was reported. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.

Time frame:
Baseline, Week 48 and 96
Reported as:
Mean · Percent Normal Dystrophin Protein Level
Change From Baseline in Dystrophin Protein Levels Quantified by Western Blot at Week 48 and 96
Percent Normal Dystrophin Protein LevelEteplirsen 30 mg/kg
Change at Week 480.102 ± 0.0896
Change at Week 960.321 ± 0.4863
SecondaryChange From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 and 96

Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry at Week 48 and 96 was reported.

Time frame:
Baseline, Week 48 and 96
Reported as:
Mean · Percent dystrophin positive fibers
Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 and 96
Percent dystrophin positive fibersEteplirsen 30 mg/kg
Change at Week 480.004 ± 0.0096
Change at Week 960.015 ± 0.0175

Adverse events

Collected over Baseline up to 100 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eteplirsen 30 mg/kg0/26 (0%)4/26 (15.4%)26/26 (100%)
Control Group (Untreated) (Non-exon 51 Amenable Participants)0/7 (0%)0/7 (0%)5/7 (71.4%)
Most frequent serious events
Most frequent serious events
EventEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
Foreign bodyInjury, poisoning and procedural complications1/260/7
Coxsackie viral infectionInfections and infestations1/260/7
InfluenzaInfections and infestations1/260/7
Rhinovirus infectionInfections and infestations1/260/7
RhabdomyolysisMusculoskeletal and connective tissue disorders1/260/7
Most frequent other events
Showing 10 of 59
Most frequent other events
EventEteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)
CoughRespiratory, thoracic and mediastinal disorders23/263/7
NasopharyngitisInfections and infestations16/262/7
RhinorrhoeaRespiratory, thoracic and mediastinal disorders13/260/7
RashSkin and subcutaneous tissue disorders13/260/7
Upper respiratory tract infectionInfections and infestations11/261/7
VomitingGastrointestinal disorders11/262/7
PyrexiaGeneral disorders11/261/7
Nasal congestionRespiratory, thoracic and mediastinal disorders10/260/7
HeadacheNervous system disorders10/260/7
FallInjury, poisoning and procedural complications9/260/7

Baseline characteristics

Full set included all participants who were enrolled in the eteplirsen group and received at least 1 dose of eteplirsen as well as all participants who were enrolled in the untreated group and had at least 1 assessment post-enrollment assessment.

Age, Continuous
Age, Continuous(years)Eteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)Total
Mean5.0 ± 0.825.0 ± 1.005.0 ± 0.85
Sex: Female, Male
Sex: Female, Male(Participants)Eteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)Total
Female000
Male26733
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)Total
Hispanic or Latino505
Not Hispanic or Latino21728
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)Total
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American101
White22628
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Eteplirsen 30 mg/kgControl Group (Untreated) (Non-exon 51 Amenable Participants)Total
United States26733
08

Study locations

13 sites
  • Neuromuscular Research Center of Arizona
    Phoenix, Arizona 85028, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • University of Florida, Shands Hospital
    Gainesville, Florida 32610, United States
  • Rare Disease Research Center
    Atlanta, Georgia 30318, United States
  • Children's Hospital of Atlanta
    Atlanta, Georgia 30324, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Shriners Hospital for Children
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Dec 2018, 41 months.

Results were first posted in Jul 2020, 1 year 7 months after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 41 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2015
First posted
Apr 17, 2015
StartActual
Jun 30, 2015
Primary completionActual
Dec 17, 2018
CompletionActual
Dec 17, 2018
Results first posted
Jul 22, 2020
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02420379
Responsible party
Sponsor
First posted
Apr 17, 2015
Start date
Jun 30, 2015
Primary completion
Dec 17, 2018
Completion
Dec 17, 2018
Results posted
Jul 22, 2020
Last update
Jan 25, 2021

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion